synthesize

{
  "ranked_hypotheses": [
    {
      "title": "CCL2-CCR2 myeloid signaling as a selective driver of fast-fatigable motor-neuron denervation as proximal driver in CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS",
      "description": "CCL2-CCR2 myeloid signaling as a selective driver of fast-fatigable motor-neuron denervation should produce a measurable proximal phenotype before late disease pathology. The decisive test is myeloid-specific CCR2 blockade with fast/slow motor-unit stratification and NMJ integrity measurements.",
      "target_gene": "CCL2-CCR2",
      "dimension_scores": {
        "evidence_strength": 0.62,
        "novelty": 0.72,
        "feasibility": 0.67,
        "therapeutic_potential": 0.64,
        "mechanistic_plausibility": 0.7,
        "druggability": 0.54,
        "safety_profile": 0.52,
        "competitive_landscape": 0.58,
        "data_availability": 0.66,
        "reproducibility": 0.61
      },
      "composite_score": 0.626,
      "evidence_for": [
        {
          "claim": "Study demonstrated CCL2-CCR2 drives NMJ denervation in ALS but noted that the mechanism of selective fast vs. slow motor neuron vulnerability downstream of this axis was not resolved.",
          "doi": "10.1038/s41467-025-62351-3",
          "source": "The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis"
        }
      ],
      "evidence_against": [
        {
          "claim": "CCR2 blockade may reduce inflammation without directly rescuing vulnerable motor-neuron physiology",
          "doi": "10.1038/s41467-025-62351-3",
          "source": "The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis"
        }
      ]
    },
    {
      "title": "Cell-state stratification is required to resolve CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS",
      "description": "The question is likely underpowered or misleading unless analyses preserve the key strata: CCL2-CCR2, NMJ, ALS, CCR2. Averaging across these strata could convert a causal subpopulation effect into a weak association.",
      "target_gene": "NMJ",
      "dimension_scores": {
        "evidence_strength": 0.58,
        "novelty": 0.64,
        "feasibility": 0.73,
        "therapeutic_potential": 0.55,
        "mechanistic_plausibility": 0.65,
        "druggability": 0.45,
        "safety_profile": 0.62,
        "competitive_landscape": 0.56,
        "data_availability": 0.7,
        "reproducibility": 0.64
      },
      "composite_score": 0.612,
      "evidence_for": [
        {
          "claim": "The open question explicitly depends on cell-type, region, or molecular-state resolution.",
          "doi": "10.1038/s41467-025-62351-3"
        }
      ],
      "evidence_against": [
        {
          "claim": "Stratified effects may reflect sampling or annotation artifacts rather than mechanism.",
          "doi": "10.1038/s41467-025-62351-3"
        }
      ]
    },
    {
      "title": "Perturbation-first validation should precede therapeutic claims for CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS",
      "description": "The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.",
      "target_gene": "ALS",
      "dimension_scores": {
        "evidence_strength": 0.55,
        "novelty": 0.6,
        "feasibility": 0.76,
        "therapeutic_potential": 0.57,
        "mechanistic_plausibility": 0.63,
        "druggability": 0.48,
        "safety_profile": 0.6,
        "competitive_landscape": 0.55,
        "data_availability": 0.68,
        "reproducibility": 0.66
      },
      "composite_score": 0.608,
      "evidence_for": [
        {
          "claim": "The proposed priority experiment is concrete: myeloid-specific CCR2 blockade with fast/slow motor-unit stratification and NMJ integrity measurements",
          "doi": "10.1038/s41467-025-62351-3"
        }
      ],
      "evidence_against": [
        {
          "claim": "Therapeutic tractability is not established by the current source evidence.",
          "doi": "10.1038/s41467-025-62351-3"
        }
      ]
    }
  ],
  "knowledge_edges": [
    {
      "source_id": "f7f8019f-08f6-428b-adff-85e8ea202b60",
      "source_type": "analysis",
      "target_id": "CCL2-CCR2",
      "target_type": "entity",
      "relation": "debate_reconstructs_evidence_for"
    },
    {
      "source_id": "f7f8019f-08f6-428b-adff-85e8ea202b60",
      "source_type": "analysis",
      "target_id": "NMJ",
      "target_type": "entity",
      "relation": "debate_reconstructs_evidence_for"
    },
    {
      "source_id": "f7f8019f-08f6-428b-adff-85e8ea202b60",
      "source_type": "analysis",
      "target_id": "ALS",
      "target_type": "entity",
      "relation": "debate_reconstructs_evidence_for"
    },
    {
      "source_id": "f7f8019f-08f6-428b-adff-85e8ea202b60",
      "source_type": "analysis",
      "target_id": "CCR2",
      "target_type": "entity",
      "relation": "debate_reconstructs_evidence_for"
    }
  ],
  "synthesis_summary": "Consensus: CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS is a valid debate target because it is anchored to The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis and asks a falsifiable question about CCL2-CCR2 myeloid signaling as a selective driver of fast-fatigable motor-neuron denervation. Dissent: the source evidence does not yet prove causality, and CCR2 blockade may reduce inflammation without directly rescuing vulnerable motor-neuron physiology. The next step is myeloid-specific CCR2 blockade with fast/slow motor-unit stratification and NMJ integrity measurements."
}